Pancreatic endocrine tumors (PETs) have long fascinated clinicians and investigators
despite their relative rarity. Their clinical presentation varies depending on whether the …

Pancreatic endocrine tumors (PETs) have long fascinated clini-cians, because some can
release biologically active hormones that cause distinct syndromes and provide important …

Pancreatic Endocrine Tumors: Expression Profiling Evidences a Role for AKT-mTOR Pathway
- PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI …

Pancreatic endocrine neoplasms (PETs) are uncommon tumors with an annual incidence
less than 1 per 100,000 persons per year in the general population. PETs that produce …

Pancreatic endocrine tumors have been steadily growing in incidence and prevalence
during the last two decades, showing an incidence of 4–5/1,000,000 population. They …

Simple Summary Pancreatic neuroendocrine tumors (pNETs) are rare, indolent cancers
whose causation is only partly understood. An increasing number of studies have uncovered …

Peptide receptor radionuclide therapy (PRRT) is a type of radiotherapy that targets peptide
receptors and is typically used for neuroendocrine tumours (NETs). Some of the key …

Neuroendocrine neoplasms (NENs) arise from cells of the neuroendocrine system located in
many sites amongst which most common are the gastrointestinal (GI) system and the lung …

Pancreatic endocrine tumors (PETs) may be part of hereditary multiple endocrine neoplasia
type 1 (MEN1) syndrome. While MEN1 gene mutation is the only ascertained genetic …

The gene expression profile of metastasizing serotonin-producing neuroendocrine
carcinomas, which arise from enterochromaffin cells in the jejunum and ileum, is still largely …